These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3141344)

  • 41. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Penetration of ciprofloxacin and metabolites into human lung, bronchial and pleural tissue after 250 and 500 mg oral ciprofloxacin.
    Rohwedder R; Bergan T; Caruso E; Thorsteinsson SB; Della Torre H; Scholl H
    Chemotherapy; 1991; 37(4):229-38. PubMed ID: 1790720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
    Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
    Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
    Kosmidis J; Gargalianos P; Adamis G; Petropoulou D; Makris D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():219-21. PubMed ID: 3144541
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():35-41. PubMed ID: 3144547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bronchial penetration of ofloxacin after single and multiple oral dosage.
    Davey PG; Precious E; Winter J
    J Antimicrob Chemother; 1991 Mar; 27(3):335-41. PubMed ID: 2037539
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fleroxacin: safety, tolerance and effect on the faecal flora of healthy volunteers.
    Shah PM; Sammann A; Schäfer V; Seczendi M; Knothe H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():209-13. PubMed ID: 3144539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Fluorometric assay for fleroxacin uptake by bacterial cells.
    Chapman JS; Georgopapadakou NH
    Antimicrob Agents Chemother; 1989 Jan; 33(1):27-9. PubMed ID: 2540707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An in vitro investigation of the intraphagocytic bioactivity of difloxacin, ciprofloxacin, pefloxacin and fleroxacin.
    van Rensburg CE; Joone G; Anderson R
    Chemotherapy; 1989; 35(4):273-7. PubMed ID: 2504545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Renal tolerance of fleroxacin in healthy volunteers.
    Mondorf AW; Buch A; Steinbacher G; Rüdel C; Falkenberg FW
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():179-89. PubMed ID: 2904925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vitro activity of fleroxacin.
    Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of fleroxacin and ciprofloxacin on the formation of human mature colonies of healthy donor versus transplanted hemopoietic progenitor cells.
    Kissling M; Herzog C; Speck B
    Chemotherapy; 1991; 37(3):212-7. PubMed ID: 1909622
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In-vitro activity of fleroxacin compared with three other quinolones.
    Bremner DA; Dickie AS; Singh KP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():19-23. PubMed ID: 3144536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of free tissue concentrations of fleroxacin after oral administration.
    Limberg J; LeBel M; Derendorf H
    Pharm Res; 1990 Apr; 7(4):422-4. PubMed ID: 2114021
    [No Abstract]   [Full Text] [Related]  

  • 57. Penetration of fleroxacin into body tissues and fluids.
    Weidekamm E; Portmann R
    Am J Med; 1993 Mar; 94(3A):75S-80S. PubMed ID: 8452186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A; Benonisen E; Salveson A; Zahm F
    Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The killing action of fleroxacin upon Bacteroides fragilis.
    Griggs DJ; Piddock LJ; Wise R
    J Antimicrob Chemother; 1989 Jan; 23(1):53-8. PubMed ID: 2501268
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Possibility for induction of convulsion by fleroxacin and its disposition in the central nervous system in animals.
    Taga F; Kobayashi F; Saito S; Ooie T; Kawahara F; Uchida H; Shimada J; Hori S; Sakai O
    Arzneimittelforschung; 1990 Aug; 40(8):900-4. PubMed ID: 2173611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.